Cost-effectiveness of immunotherapies for advanced squamous non-small cell lung cancer: a systematic review
Abstract Background There are differences in the pharmacoeconomics of Immune checkpoint blocking (ICB) therapies for the treatment of lung squamous cell carcinoma (LSCC). However, no corresponding review studies have fully discussed the cost-effectiveness of ICBs in treating LSCC. The aim of this pa...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2024-03-01
|
| Series: | BMC Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12885-024-12043-w |
| _version_ | 1797266779521679360 |
|---|---|
| author | Minyu Cheng Yanfei Shao Li Li Menglao Jiang Zhouye Song |
| author_facet | Minyu Cheng Yanfei Shao Li Li Menglao Jiang Zhouye Song |
| author_sort | Minyu Cheng |
| collection | DOAJ |
| description | Abstract Background There are differences in the pharmacoeconomics of Immune checkpoint blocking (ICB) therapies for the treatment of lung squamous cell carcinoma (LSCC). However, no corresponding review studies have fully discussed the cost-effectiveness of ICBs in treating LSCC. The aim of this paper is to systematically review and evaluate all available pharmacoeconomic studies of ICBs for LSCC. Method The inclusion criteria were based on the population, intervention, comparator, outcomes, and study designs. An electronic search was conducted by June 2023, and the following databases were used: PubMed, EMBASE, Cochrane Library, and Web of Science. Search keywords included ‘Carcinoma’, Non-Small-Cell Lung’, ‘Immunotherapy’, and ‘Economics, Medical’. The primary outcome was the cost-effectiveness analysis of ICB therapy in LSCC patients. Drummond Checklist was used to assess quality problems and possible bias in the study design of included pharmacoeconomic studies. Results This review searched 15 articles on the economic evaluation of ICB treatment for LSCC. After a qualitative review of 15 studies, we concluded that nivolumab is more cost-effective as a monotherapy than chemotherapy alone. In the combination regimen, pembrolizumab combined with chemotherapy appears to be the most cost-effective option at present, but for Chinese payers with LSCC, locally developed treatments such as sintilimab or toripalimab in combination with chemotherapy are more cost-effective. Discussion The inclusion of economic evaluation has heterogeneity in research design and outcomes, which can only support qualitative synthesis. Therefore, The results of this paper need to be treated with caution. For the Chinese market, instead of imported drugs, the possible cost-effectiveness of locally developed ICB therapies should be the focus of future research. |
| first_indexed | 2024-04-25T01:06:07Z |
| format | Article |
| id | doaj.art-8cc41ecfc27f4cd68c7066f4168c18c0 |
| institution | Directory Open Access Journal |
| issn | 1471-2407 |
| language | English |
| last_indexed | 2024-04-25T01:06:07Z |
| publishDate | 2024-03-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Cancer |
| spelling | doaj.art-8cc41ecfc27f4cd68c7066f4168c18c02024-03-10T12:14:53ZengBMCBMC Cancer1471-24072024-03-0124111410.1186/s12885-024-12043-wCost-effectiveness of immunotherapies for advanced squamous non-small cell lung cancer: a systematic reviewMinyu Cheng0Yanfei Shao1Li Li2Menglao Jiang3Zhouye Song4Department of Pharmacy, Zhejiang HospitalDepartment of Pharmacy, Zhejiang Provincial Peopleʼs HospitalDepartment of Pharmacy, Zhejiang HospitalZhejiang Center of Drug and Cosmetics EvaluationDepartment of Pharmacy, Zhejiang HospitalAbstract Background There are differences in the pharmacoeconomics of Immune checkpoint blocking (ICB) therapies for the treatment of lung squamous cell carcinoma (LSCC). However, no corresponding review studies have fully discussed the cost-effectiveness of ICBs in treating LSCC. The aim of this paper is to systematically review and evaluate all available pharmacoeconomic studies of ICBs for LSCC. Method The inclusion criteria were based on the population, intervention, comparator, outcomes, and study designs. An electronic search was conducted by June 2023, and the following databases were used: PubMed, EMBASE, Cochrane Library, and Web of Science. Search keywords included ‘Carcinoma’, Non-Small-Cell Lung’, ‘Immunotherapy’, and ‘Economics, Medical’. The primary outcome was the cost-effectiveness analysis of ICB therapy in LSCC patients. Drummond Checklist was used to assess quality problems and possible bias in the study design of included pharmacoeconomic studies. Results This review searched 15 articles on the economic evaluation of ICB treatment for LSCC. After a qualitative review of 15 studies, we concluded that nivolumab is more cost-effective as a monotherapy than chemotherapy alone. In the combination regimen, pembrolizumab combined with chemotherapy appears to be the most cost-effective option at present, but for Chinese payers with LSCC, locally developed treatments such as sintilimab or toripalimab in combination with chemotherapy are more cost-effective. Discussion The inclusion of economic evaluation has heterogeneity in research design and outcomes, which can only support qualitative synthesis. Therefore, The results of this paper need to be treated with caution. For the Chinese market, instead of imported drugs, the possible cost-effectiveness of locally developed ICB therapies should be the focus of future research.https://doi.org/10.1186/s12885-024-12043-wCost-effectivenessImmunotherapyNon-small cell lung cancerNivolumabPembrolizumabSintilimab |
| spellingShingle | Minyu Cheng Yanfei Shao Li Li Menglao Jiang Zhouye Song Cost-effectiveness of immunotherapies for advanced squamous non-small cell lung cancer: a systematic review BMC Cancer Cost-effectiveness Immunotherapy Non-small cell lung cancer Nivolumab Pembrolizumab Sintilimab |
| title | Cost-effectiveness of immunotherapies for advanced squamous non-small cell lung cancer: a systematic review |
| title_full | Cost-effectiveness of immunotherapies for advanced squamous non-small cell lung cancer: a systematic review |
| title_fullStr | Cost-effectiveness of immunotherapies for advanced squamous non-small cell lung cancer: a systematic review |
| title_full_unstemmed | Cost-effectiveness of immunotherapies for advanced squamous non-small cell lung cancer: a systematic review |
| title_short | Cost-effectiveness of immunotherapies for advanced squamous non-small cell lung cancer: a systematic review |
| title_sort | cost effectiveness of immunotherapies for advanced squamous non small cell lung cancer a systematic review |
| topic | Cost-effectiveness Immunotherapy Non-small cell lung cancer Nivolumab Pembrolizumab Sintilimab |
| url | https://doi.org/10.1186/s12885-024-12043-w |
| work_keys_str_mv | AT minyucheng costeffectivenessofimmunotherapiesforadvancedsquamousnonsmallcelllungcancerasystematicreview AT yanfeishao costeffectivenessofimmunotherapiesforadvancedsquamousnonsmallcelllungcancerasystematicreview AT lili costeffectivenessofimmunotherapiesforadvancedsquamousnonsmallcelllungcancerasystematicreview AT menglaojiang costeffectivenessofimmunotherapiesforadvancedsquamousnonsmallcelllungcancerasystematicreview AT zhouyesong costeffectivenessofimmunotherapiesforadvancedsquamousnonsmallcelllungcancerasystematicreview |